Mustang Bio, Inc. (MBIO): Price and Financial Metrics
MBIO Price/Volume Stats
| Current price | $5.55 | 52-week high | $14.10 |
| Prev. close | $6.26 | 52-week low | $2.82 |
| Day low | $5.51 | Volume | 54,500 |
| Day high | $6.29 | Avg. volume | 47,911 |
| 50-day MA | $4.45 | Dividend yield | N/A |
| 200-day MA | $7.02 | Market Cap | 45.29M |
MBIO Stock Price Chart Interactive Chart >
Mustang Bio, Inc. (MBIO) Company Bio
Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.
Latest MBIO News From Around the Web
Below are the latest news stories about MUSTANG BIO INC that investors may wish to consider to help them evaluate MBIO as an investment opportunity.
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio UpdatesuBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support MB-106 and future pipeline Company optimizes resources to focus on advancing lead CD20 CAR T program, GBM program, and in vivo CAR T platform technology from Mayo Clinic Transaction and partnership with uBriGene, portfolio optimization, restructuring and recent loan repayment expected to significantly r |
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsFortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, May 15, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and p |
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsWORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “The |
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell TherapyData from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that |
Mustang Bio Announces Reverse Stock SplitWORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will effect a 15-for-1 reverse stock split of its issued and outstanding common stock. Mustang expects its common stock to begin trading on a split-adj |
MBIO Price Returns
| 1-mo | 32.46% |
| 3-mo | -31.57% |
| 6-mo | -21.53% |
| 1-year | -40.71% |
| 3-year | -90.11% |
| 5-year | -94.99% |
| YTD | -6.31% |
| 2022 | -76.21% |
| 2021 | -56.14% |
| 2020 | -7.23% |
| 2019 | 38.78% |
| 2018 | -75.48% |
Continue Researching MBIO
Want to see what other sources are saying about Mustang Bio Inc's financials and stock price? Try the links below:Mustang Bio Inc (MBIO) Stock Price | Nasdaq
Mustang Bio Inc (MBIO) Stock Quote, History and News - Yahoo Finance
Mustang Bio Inc (MBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...